Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.22.1
Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2019 $ 0 $ 495 $ (8,055) $ (7,560)
Balance (in shares) at Dec. 31, 2019 2,852,485      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock in exchange for in-process research and development $ 0 2,126 0 2,126
Issuance of common stock in exchange for in-process research and development (in shares) 891,422      
Gain on note extinguishment $ 0 971 0 971
Conversion of convertible notes into common stock upon close of the merger $ 0 6,953 0 6,953
Conversion of convertible notes into common stock upon close of the merger (in shares) 977,128      
Issuance of common stock and warrants in connection with pre-merger financing $ 1 (1) 0 0
Issuance of common stock and warrants in connection with pre-merger financing (in shares) 4,999,988      
Issuance costs attributed to pre-merger financing $ 0 (1,080) 0 (1,080)
Issuance of common stock, warrants and options to former Rexahn stockholders and effect of asset acquisition $ 0 8,115 0 8,115
Issuance of common stock, warrants and options to former Rexahn stockholders and effect of asset acquisition (in shares) 1,120,800      
Share-based compensation $ 0 1,506 0 1,506
Reclassification of warrants from liability to equity 0 64 0 64
Exercise of stock options $ 0 58 0 58
Exercise of stock options (in shares) 40,672      
Net and comprehensive loss $ 0 0 (24,620) (24,620)
Balance at Dec. 31, 2020 $ 1 19,207 (32,675) (13,467)
Balance (in shares) at Dec. 31, 2020 10,882,495      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Reclassification of Series A warrant liability to equity $ 0 61,793 0 61,793
Issuance of common stock and warrants in connection with registered direct offering $ 1 14,999 0 15,000
Issuance of common stock and warrants in connection with registered direct offering (in shares) 3,076,923      
Issuance of common stock in connection with the at-the-market program $ 0 13,491 0 13,491
Issuance of common stock in connection with the at-the-market program (in shares) 2,778,890      
Issuance of common stock in connection with settlement with investors $ 0 1,614 0 1,614
Issuance of common stock in connection with settlement with investors (in shares) 350,000      
Issuance costs $ 0 (1,517) 0 (1,517)
Exercise of Series B warrants $ 0 0 0 0
Exercise of Series B warrants (in shares) 1,629,634      
Share-based compensation $ 0 1,914 0 1,914
Share-based compensation (in shares) 54,444      
Exercise of stock options $ 0 87 0 87
Exercise of stock options (in shares) 73,442      
Net and comprehensive loss $ 0 0 (56,693) (56,693)
Balance at Dec. 31, 2021 $ 2 $ 111,588 $ (89,368) $ 22,222
Balance (in shares) at Dec. 31, 2021 18,845,828